CoV-2 Envelope (1-75)
E.Coli
Protein is >90% pure as determined SDS-PAGE.
Description
The E.coli derived recombinant protein contains the Coronavirus 2019 CoV-2 Envelope, Wuhan-Hu-1 strain, amino acids 1-75 fused to GST-tag at N-terminal & His-tag at C-terminal having a calculated Mw of 36.8 kDa and migrating between 33-35 umder reducing condition.
Product Specs
The 2019 novel coronavirus (2019-nCoV), a human-infecting coronavirus responsible for causing viral pneumonia, was first identified in December 2019 in a fish market located in Wuhan, Hubei province, China.
Genetic analysis reveals that 2019-nCoV shares 87% of its identity with the bat-derived severe acute respiratory syndrome coronavirus 2018 (SARS-CoV-2), which was discovered in Zhoushan, eastern China. Despite some amino acid variations, the receptor-binding domain (RBD) structure of 2019-nCoV closely resembles that of 2018 SARS-CoV. This similarity suggests that 2019-nCoV may also target the angiotensin-converting enzyme 2 (ACE2) receptor protein in humans.
Bats are considered a likely natural reservoir for 2019-nCoV. However, researchers hypothesize that an intermediate animal host, potentially from those sold at the seafood market, played a role in transmitting the virus to humans. Notably, studies indicate that the 2019-nCoV genome is a product of recombination, particularly within the spike glycoprotein, involving a bat coronavirus and an unknown coronavirus.
This product consists of a recombinant protein derived from E. coli. It comprises the Envelope protein of the Coronavirus 2019 (CoV-2), specifically the Wuhan-Hu-1 strain, encompassing amino acids 1 to 75. The protein is fused with a GST-tag at the N-terminal and a His-tag at the C-terminal. Its calculated molecular weight is 36.8 kDa, and under reducing conditions, it migrates between 33-35 kDa on SDS-PAGE.
The CoV-2 Envelope protein is provided in a buffer solution containing 20mM Tris, 5mM EDTA, 0.5M Arginine at pH 8, and 10% sucrose.
The lyophilized CoV-2 Envelope protein remains stable at room temperature for up to 3 weeks. However, it is recommended to store it desiccated at a temperature below -18°C. Once reconstituted, the CoV2 Envelope protein should be stored at 4°C for 2-7 days. For long-term storage, it is advisable to store it below -18°C. To enhance stability during long-term storage, consider adding a carrier protein such as 0.1% HSA or BSA. Avoid repeated freeze-thaw cycles to maintain protein integrity.
To prepare a working stock solution, add deionized water to the lyophilized pellet to achieve a concentration of approximately 0.5mg/ml. Allow the pellet to dissolve completely before use.
Analysis by SDS-PAGE indicates that the protein purity is greater than 90%.
E.Coli
Purified by Metal-Afinity chromatographic technique.
Product Science Overview
The Coronavirus 2019 Envelope (E) protein, specifically the recombinant form encompassing amino acids 1-75, plays a crucial role in the life cycle of the virus. This protein is integral to the structure and function of the virus, contributing to its assembly, budding, and pathogenesis.
The E protein is a small, integral membrane protein that is involved in several critical aspects of the virus’s life cycle. It is known for its role in:
- Assembly: The E protein aids in the assembly of the virus particles.
- Budding: It is involved in the budding process, where new viral particles exit the host cell.
- Envelope Formation: The protein contributes to the formation of the viral envelope, which is essential for the virus’s infectivity.
- Pathogenesis: The E protein is also implicated in the pathogenesis of the virus, influencing its ability to cause disease .
Recent studies have expanded our understanding of the E protein’s structural motifs and topology. It functions as an ion-channelling viroporin, interacting with other coronavirus proteins and host cell proteins . For instance, the palmitoylation of the SARS-CoV-2 E protein at specific cysteine residues is crucial for its stability and interaction with other structural proteins, which is vital for the production of virus-like particles .
